Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Recognized by America's Top Doctors 2015 – 2017
Recognized in Philadelphia magazine's annual Top Docs issues for 2018 and 2019
Medical Oncology, 2001
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Clinical trials in non-Hodgkin's lymphoma, phase I, II and III
Hivnor CM, Nguyen V, Rook AH, Junkins-Hopkins J, Gelfand JM, Nasta S, Frank I, Kim EM: CD8+ lymphoma in a patient with human immunodeficiency virus Arch Dermatol 141 (10): 1321-2,2005.
Tsai DE, Aqui NA, Vogl DT, Bloom RD, Schuster SJ, Nasta SD, Wasik MA: Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene.
Am J Transplant 5 (8): 2070-3,2005.
Vogl DT, Glatstein E, Carver JR, Schuster SJ, Stadtmauer EA, Luger S, Nasta SD, Porter DL, Elstrom R, Tsai DE: Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.
Leuk Lymphoma. 46 (9): 1313-20,2005.
Loren AW, Luger SM, Stadtmauer EA, Tsai DE, Schuster S, Nasta SD, Goldstein SC, Perl A, Orloff G, Oliver JC, Green J, Emerson SG, Porter DL: Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
Bone Marrow Transplantation 35 (9): 921-6,2005.
Tsai DE, Maillard I, Downs LH, Alavi A, Nasta SD, Glatstein E, Schuster SJ: Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia.
Leuk Lymphoma. 45 (3): 591-5,2004.
Nasta SD, Hoff PM, GeorgeCM, Neubauer, M, Cohen SC, Abbruzzese JA, Winn R., Pazdur RM: “Phase II Study of MGI-114 Administered Intravenously for Five Days Every 28 Days to Patients with Metastatic Colorectal Cancer” Am J Clin Oncol. 26 (2): 132-4,2003.
Nasta SD, Carrum G., Shahab I., Hanania N, Udden MM: “Regression of a Plasmablastic Lymphoma in a Patient with HIV on Highly Active Antiretroviral Therapy” Leuk Lymphoma 43 (2): 423-426,2002.
Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA: “ Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease" Bone Marrow Transplant 30 (1): 23-28,2002.
Dwivedy, S: “Hodgkin’s Disease: Clinical Management and Future Perspectives” Fellows Reporter 6 (3): 2001.
Dwivedy S, . Hoff P. M, Dumas P., . Lassere Y, . Aguayo A, . Hayakawa T, Abbruzzese J.L.: Safety and phamacokinetics (PK) of an antitumor/antiangiogenic agent, TAS-102: a phase I study for patients(pts) with solid tumors ASCO : 2001.
Division of Hematology OncologyPerelman Center for Advanced Medicine12th Floor, South PavilionOffice #12-1593400 Civic Center Boulevard
Phone: (215) 662-3933
Patient appointments: 800-789-7366